Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Thomas Brandt

Cardiovascular Disease Council Bluffs, IA Medical Doctor

NPI 1992746416 CMS profile 960989

1 Edmundson Pl, Suite 306, Council Bluffs, IA 51503

Open in the dashboard

General payments

$2,604

154 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Thomas Brandt of Council Bluffs, IA is reported in the CMS Open Payments database as having received $2,604 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $270 12
2021 General $100 6
2020 General $310 16
2019 General $1,924 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Brandt
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Thomas Brandt were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Thomas Brandt Cardiovascular Disease median Middle half National median
2019 $1,924 $450 $127–$1,392 $163
2020 $310 $242 $77–$751 $114
2021 $100 $335 $101–$1,037 $132
2022 $270 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Pfizer Inc. $389 19 payments
  2. E.R. Squibb & Sons, L.L.C. $290 17 payments
  3. Amgen Inc. $272 20 payments
  4. Janssen Pharmaceuticals, Inc $228 19 payments
  5. Novartis Pharmaceuticals Corporation $179 17 payments
  6. Medtronic Vascular, Inc. $177 2 payments
  7. Abbott Laboratories $155 2 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $128 11 payments
  9. Novo Nordisk Inc $103 7 payments
  10. Sanofi-Aventis U.S. LLC $91 1 payment
  11. Other $593 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,604 154 payments
Products named General payments · program years 2019–2022
  1. ELIQUIS Cardiovascular;Metabolic Disease $366 17 payments
  2. ELIQUIS Cardiovascular $290 17 payments
  3. XARELTO $228 19 payments
  4. Repatha $205 16 payments
  5. CoreValve Evolut $177 2 payments
  6. ENTRESTO $151 15 payments
  7. CardioMEMS HF System $130 1 payment
  8. LifeVest $128 11 payments
  9. Ozempic $103 7 payments
  10. Corlanor $100 8 payments
  11. Other $1,100 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record